Oral probiotics in coronavirus disease 2019: connecting the gut–lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials

Defined as helpful live bacteria that can provide medical advantages to the host when administered in tolerable amounts, oral probiotics might be worth considering as a possible preventive or therapeutic modality to mitigate coronavirus disease 2019 (COVID-19) symptom severity. This hypothesis stems...

Descripción completa

Detalles Bibliográficos
Autores principales: Baindara, P., Chakraborty, R., Holliday, Z.M., Mandal, S.M., Schrum, A.G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785423/
https://www.ncbi.nlm.nih.gov/pubmed/33425362
http://dx.doi.org/10.1016/j.nmni.2021.100837
_version_ 1783632440479186944
author Baindara, P.
Chakraborty, R.
Holliday, Z.M.
Mandal, S.M.
Schrum, A.G.
author_facet Baindara, P.
Chakraborty, R.
Holliday, Z.M.
Mandal, S.M.
Schrum, A.G.
author_sort Baindara, P.
collection PubMed
description Defined as helpful live bacteria that can provide medical advantages to the host when administered in tolerable amounts, oral probiotics might be worth considering as a possible preventive or therapeutic modality to mitigate coronavirus disease 2019 (COVID-19) symptom severity. This hypothesis stems from an emerging understanding of the gut–lung axis wherein probiotic microbial species in the digestive tract can influence systemic immunity, lung immunity, and possibly viral pathogenesis and secondary infection co-morbidities. We review the principles underlying the gut–lung axis, examples of probiotic-associated antiviral activities, and current clinical trials in COVID-19 based on oral probiotics.
format Online
Article
Text
id pubmed-7785423
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-77854232021-01-06 Oral probiotics in coronavirus disease 2019: connecting the gut–lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials Baindara, P. Chakraborty, R. Holliday, Z.M. Mandal, S.M. Schrum, A.G. New Microbes New Infect Editorial Defined as helpful live bacteria that can provide medical advantages to the host when administered in tolerable amounts, oral probiotics might be worth considering as a possible preventive or therapeutic modality to mitigate coronavirus disease 2019 (COVID-19) symptom severity. This hypothesis stems from an emerging understanding of the gut–lung axis wherein probiotic microbial species in the digestive tract can influence systemic immunity, lung immunity, and possibly viral pathogenesis and secondary infection co-morbidities. We review the principles underlying the gut–lung axis, examples of probiotic-associated antiviral activities, and current clinical trials in COVID-19 based on oral probiotics. Elsevier 2021-01-06 /pmc/articles/PMC7785423/ /pubmed/33425362 http://dx.doi.org/10.1016/j.nmni.2021.100837 Text en © 2021 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Editorial
Baindara, P.
Chakraborty, R.
Holliday, Z.M.
Mandal, S.M.
Schrum, A.G.
Oral probiotics in coronavirus disease 2019: connecting the gut–lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials
title Oral probiotics in coronavirus disease 2019: connecting the gut–lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials
title_full Oral probiotics in coronavirus disease 2019: connecting the gut–lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials
title_fullStr Oral probiotics in coronavirus disease 2019: connecting the gut–lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials
title_full_unstemmed Oral probiotics in coronavirus disease 2019: connecting the gut–lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials
title_short Oral probiotics in coronavirus disease 2019: connecting the gut–lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials
title_sort oral probiotics in coronavirus disease 2019: connecting the gut–lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785423/
https://www.ncbi.nlm.nih.gov/pubmed/33425362
http://dx.doi.org/10.1016/j.nmni.2021.100837
work_keys_str_mv AT baindarap oralprobioticsincoronavirusdisease2019connectingthegutlungaxistoviralpathogenesisinflammationsecondaryinfectionandclinicaltrials
AT chakrabortyr oralprobioticsincoronavirusdisease2019connectingthegutlungaxistoviralpathogenesisinflammationsecondaryinfectionandclinicaltrials
AT hollidayzm oralprobioticsincoronavirusdisease2019connectingthegutlungaxistoviralpathogenesisinflammationsecondaryinfectionandclinicaltrials
AT mandalsm oralprobioticsincoronavirusdisease2019connectingthegutlungaxistoviralpathogenesisinflammationsecondaryinfectionandclinicaltrials
AT schrumag oralprobioticsincoronavirusdisease2019connectingthegutlungaxistoviralpathogenesisinflammationsecondaryinfectionandclinicaltrials

Ejemplares similares